

Progenics Cord Blood Cryobank 2023 Annual Quality Report



Company Profile

Progenics Cord Blood Cryobank is a leader in delivering consistent, high quality cord blood processing results, with over 20 years of experience in the cord blood banking industry. Progenics is AABB and FACT Accredited and is registered with both Health Canada and the Food and Drug Administration (FDA) in the United States. The company's mission is to provide the highest quality processing and long-term safe, secure storage of cord blood stem cells, to ensure their availability when needed.

Progenics Cord Blood Cryobank's *modified double stem cell extraction processing technique*, developed by the company's Research and Development Team, ensures that we can guarantee every processed cord blood sample will have a minimum yield of 85% Total Nucleated Cells (TNC).

Contact Us:

Toll Free: 1-866-921-1666

Phone: 416-221-1666

Email: info@progenics.ca

Address: 701 Sheppard Avenue East
Suite 310,
Toronto, ON M2K 2Z3
Canada

Website: www.progenics.ca

Report Summary

This quality report summarizes the processing results from all the cord blood samples processed by Progenics Cord Blood Cryobank from year 2023. The quality indicators referenced in this report present 5 key variables: The Yield (%) of Total Nucleated Cells (TNC), Total Nucleated Cell Viability, CD34+ Viability, Total Nucleated Cell Count, and Viable CD34+ Cell Count.

This report also compares the average monthly and annual percentage yields of TNC including stem cells, the average percentage of total nucleated cell viability, and the average percentage of viable CD34+ cells.

Progenics uses a *modified double stem cell extraction processing technique* which ensures that a higher number of viable nucleated cells are banked for potential medical need. Based on this technique, the average recovery rate for TNCs banked has been 94.86%, which is significantly greater than the industry and shows our dedication to maintaining the highest quality standards for each client.

From 2005, 2011, 2012, and 2013, a selection of Cord Blood Units has been tested as part of the Progenics Stability Program to ensure ongoing acceptability of current parameters following cryopreservation. These tests have revealed that the average TNC Viability (%) is 70%, and the CD34+ Viability (%) is 92.78%.

2023 Monthly Report

Month	Total Nucleated Cells (TNC) Yield (%)	Total Nucleated Cell Count (x10 ⁶ /unit)	Viable CD34+ Cell Count (x10 ⁶ /unit)	Total Nucleated Cell Viability (%)	CD34+ Viability (%)
January	94.86	555.88	1.39	91.13	98.33
February	93.17	649.75	1.51	93.81	98.62
March	94.90	670.05	2.16	95.08	98.33
April	94.96	863.13	3.21	95.33	99.14
May	97.14	748.80	3.52	93.59	99.30
June	96.78	678.58	1.66	91.53	98.14
July	96.76	761.32	2.79	90.92	98.08
August	95.03	735.80	3.66	95.36	97.28
September	93.93	679.05	2.43	95.42	98.13
October	93.53	722.57	2.69	94.79	97.62
November	93.37	643.67	1.89	94.86	99.63
December	93.90	548.78	1.50	92.73	98.97
Annual Average	94.86	688.12	2.37	93.71	98.46


Notes:

TNC TNC includes all nucleated cells such as stem cells and nucleated red blood cells.


CD34+ Cells Hematopoietic Progenitor Cells


Viability Cell viability is the percentage of viable cells in a processed cord blood sample. The viability of cells is evaluated by either measurement of cell membrane integrity or by measuring certain functions of the cells from a total cell sample.

2023 Progenics Cord Blood Cryobank Post-Process Cord Blood TNC Viability



2023 Progenics Cord Blood Cryobank Post-Process Total Nucleated Cell(TNC) Yield





Conclusion: Comparing Annual Averages

Based on the above data, we confidently report that for (2023), the annual averages are determined for the following parameters:

Parameter	Annual Average	International FACT Accreditation Standard Requirements
Total Nucleated Cells Yield	94.86%	≥60%
Total Nucleated Cell Viability	93.71%	≥85%
CD34+ Cell Viability	98.46%	n/a
Total Nucleated Cell Count	6.88 x 10⁸/unit	≥5.0 x 10 ⁸ /unit
Viable CD34+ Cell Count	2.37 x 10⁶/unit	≥1.25 x 10 ⁶ /unit

The above results have been made possible due to our *modified double stem*

cell extraction processing technique which surpasses our internal quality standards by over 10%.

Progenics quality policy assures that processed cord blood units (CBU) will contain a minimum of 85% yield of total nucleated cells (TNC). Once a client's CBU has been processed, and all processing parameters meet our cord blood bank acceptance criteria, the client will receive a *Certificate of Quality* which contains quality indicators of cord blood processing results.

After reviewing the data within this report, we can confidently claim that we offer our clients the highest consistent quality of cord blood processing results.